COVAX & Team Europe ‘Not Structural Solutions’ To COVID-19 Vaccine Inequity
The medicines access organization, WEMOS, says that COVAX and “Team Europe” are welcome initiatives but they do not address the longer-term issues involved in making countries more self-sufficient in COVID-19 vaccine manufacturing. The organization has set up a website to analyze the various initiatives under way to make vaccines available to less wealthy countries.
You may also be interested in...
Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.
The key themes of France’s latest initiative on shortages are repatriating the production of certain essential medicines and their active substances, earlier detection of potential supply problems, and more effective and transparent communications with all actors in the supply chain.
New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.